LAKANA试验的统计分析计划:一项在马里1-11月龄婴儿中测试阿奇霉素大规模给药对死亡率及其他结局影响的整群随机、安慰剂对照、双盲、平行组、三臂临床试验
LAKANA试验旨在评估在马里1-11月龄婴儿中开展阿奇霉素大规模给药的有效性和安全性及其对耐药的影响,并制定统计分析计划。该试验为整群随机、安慰剂对照、双盲、平行组、三臂设计,村庄按3:4:2比例随机分配至安慰剂组、每年两次阿奇霉素给药组和每季度阿奇霉素给药组,主要结局为意向性治疗人群的死亡率,采用混合效应泊松模型评估相对风险降低。
要点
- LAKANA试验比较安慰剂、每年两次和每季度阿奇霉素大规模给药对1-11月龄婴儿死亡率的影响。
- 主要分析采用混合效应泊松模型,以村庄为随机截距,人年为偏移变量,评估相对风险降低。
- 统计分析计划在数据收集完成前制定,以避免报告偏倚和数据驱动分析。
核心结论
- 在数据收集完成前制定的统计分析计划有助于避免主要和次要目标的报告偏倚及数据驱动分析。
- 若实际分析方法与计划有偏离,将在试验结果发表时予以说明和论证。
研究设计与样本
- LAKANA为整群随机、安慰剂对照、双盲、平行组、三臂临床试验,在马里高死亡率且已实施季节性疟疾化学预防项目的地区开展。
- 参与村庄按3:4:2比例随机分配至安慰剂对照组、每年两次阿奇霉素给药组和每季度阿奇霉素给药组。
- 研究对象为1-11月龄婴儿,主要结局为意向性治疗人群的死亡率。
主要发现
- 原文未报告结果数据。
关键数值与推荐
- 采用混合效应泊松模型评估研究组间的相对风险降低,以村庄为随机截距,使用对数连接函数并以人年为偏移变量。
- 次要目标相关结局采用广义线性模型分析,并考虑聚集效应。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Large-scale Assessment of the Key health-promoting Activities of two New mass drug administration regimens with Azithromycin (LAKANA) trial in Mali aims to evaluate the efficacy and safety of azithromycin (AZI) mass drug administration (MDA) to 1-11-month-old infants as well as the impact of the intervention on antimicrobial resistance (AMR) and mechanisms of action of azithromycin. To improve the transparency and quality of this clinical trial, we prepared this statistical analysis plan (SAP). METHODS/DESIGN: LAKANA is a cluster randomized trial that aims to address the mortality and health impacts of biannual and quarterly AZI MDA. AZI is given to 1-11-month-old infants in a high-mortality setting where a seasonal malaria chemoprevention (SMC) program is in place. The participating villages are randomly assigned to placebo (control), two-dose AZI (biannual azithromycin-MDA), and four-dose AZI (quarterly azithromycin-MDA) in a 3:4:2 ratio. The primary outcome of the study is mortality among the intention-to-treat population of 1-11-month-old infants. We will evaluate relative risk reduction between the study arms using a mixed-effects Poisson model with random intercepts for villages, using log link function with person-years as an offset variable. We will model outcomes related to secondary objectives of the study using generalized linear models with considerations on clustering. CONCLUSION: The SAP written prior to data collection completion will help avoid reporting bias and data-driven analysis for the primary and secondary aims of the trial. If there are deviations from the analysis methods described here, they will be described and justified in the publications of the trial results. TRIAL REGISTRATION: ClinicalTrials.gov ID NCT04424511 . Registered on 11 June 2020.
引用
- Luoma J, Adubra L, Alber D, et al. Statistical analysis plan for the LAKANA trial: a cluster-randomized, placebo-controlled, double-blinded, parallel group, three-arm clinical trial testing the effects of mass drug administration of azithromycin on mortality and other outcomes among 1-11-month-old infants in Mali. Trials. 2023. PMID: 37968741. doi:10.1186/s13063-023-07771-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。